<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03938662</url>
  </required_header>
  <id_info>
    <org_study_id>UCDragisaMisovic</org_study_id>
    <nct_id>NCT03938662</nct_id>
  </id_info>
  <brief_title>S-adenosylmethionine Plus Choline in Treatment of Patients With Alcoholic Liver Disease</brief_title>
  <official_title>Randomised Controlled Trial Assessing the Effect of S-adenosylmethionine Plus Choline in Treatment of Patients With Alcoholic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Clinic Dr Dragisa Misovic-Dedinje</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Clinic Dr Dragisa Misovic-Dedinje</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the effect of treatment with formulation containing S-Adenosyl
      methionine and choline, on patients with alcoholic liver disease.

      Half of the patients included will receive named formulation once daily for 24 weeks while
      other half will receive placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Choline and S-Adenosyl methionine are nutrients both showing hepatoprotective effects.

      Choline helps liver metabolise glucose and lipids and repair cell membrane. S-Adenosyl
      methionine is essential for the synthesis of glutathione, a main cellular antioxidant showing
      its protective effect against free radicals, among others in liver tissue. Furthermore
      S-Adenosyl methionine is involved in regulation of hepatocyte growth, differentiation, and
      death. It also enables endogenous production of small amount of choline. Although human
      organism has capacity for production of small amount of S-Adenosyl methionine, damaged liver
      can not produce it or produce it insufficient amounts.

      Having this in mind it can be hypothesised that administration of choline and S-Adenosyl
      methionine can be beneficial in patients with alcoholic liver disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 9, 2019</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alanine aminotransferase (ALT)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Alanine aminotransferase will be measured at the enrolment and after 24 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aspartate aminotransferase (AST)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Aspartate aminotransferase will be measured at the enrolment and after 24 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-glutamyl transferase (GGT)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Gamma-glutamyl transferase will be measured at the enrolment and after 24 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline phosphatase (ALP)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Alkaline phosphatase will be measured at the enrolment and after 24 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum bilirubin</measure>
    <time_frame>24 weeks</time_frame>
    <description>Bilirubin levels will be measured at the enrolment and after 24 weeks of treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum proteins</measure>
    <time_frame>24 week</time_frame>
    <description>Serum proteins will be measured at the enrolment and after 24 weeks of treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum albumins</measure>
    <time_frame>24 week</time_frame>
    <description>Serum albumins will be measured at the enrolment and after 24 weeks of treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum cholesterol</measure>
    <time_frame>24 week</time_frame>
    <description>Serum cholesterol will be measured at the enrolment and after 24 weeks of treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum triglycerides</measure>
    <time_frame>24 week</time_frame>
    <description>Serum triglycerides will be measured at the enrolment and after 24 weeks of treatment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Alcoholic Liver Diseases</condition>
  <arm_group>
    <arm_group_label>S-Adenosyl methionine and choline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in will be administered with formulation of 100 mg of S-Adenosyl methionine and 82.5 mg of choline, once daily for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in will be administered with placebo once daily for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>formulation containing S-Adenosyl methionine and choline</intervention_name>
    <description>Patients will be administered with formulation containing S-Adenosyl methionine and choline once daily for the period of 24 weeks.</description>
    <arm_group_label>S-Adenosyl methionine and choline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of same appearance, colour and taste,</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  alcoholic liver disease

        Exclusion Criteria:

          -  hepatitis B

          -  hepatitis C

          -  autoimmune hepatitis

          -  hemochromatosis

          -  Wilson's disease

          -  hepatocellular carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nikola Panic, PhD</last_name>
    <phone>+381 11 3630600</phone>
    <email>nikola.panicmail@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Clinic Dr Dragisa Misovic-Dedinje</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikola Panic, PhD</last_name>
      <phone>+381643509133</phone>
      <email>nikola.panicmail@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Serbia</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>May 25, 2019</last_update_submitted>
  <last_update_submitted_qc>May 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Clinic Dr Dragisa Misovic-Dedinje</investigator_affiliation>
    <investigator_full_name>Nikola Panic</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>alcoholic liver diseases</keyword>
  <keyword>S-Adenosyl methionine</keyword>
  <keyword>choline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

